Buy Rating on Tyra Biosciences Driven by Dabogratinib’s Differentiated FGFR3 Profile and Key Near-Term Phase II Catalyst

William Blair analyst Sami Corwin has maintained their bullish stance on TYRA stock, giving a Buy rating on February 13.

Sami Corwin has given his Buy rating due to a combination of factors tied to Tyra’s lead asset, dabogratinib, and its differentiated FGFR3-selective profile. He views the drug as having clear first-in-class and best-in-class potential across intermediate-risk non-muscle-invasive bladder cancer, low-grade upper tract urothelial carcinoma, and achondroplasia, supported by emerging mechanism and clinical data that validate FGFR3 as a value-creating target.

Corwin also emphasizes that dabogratinib’s selectivity should enable higher dosing and deeper target engagement than earlier pan-FGFR agents, driving a more favorable efficacy–tolerability balance. In addition, he highlights near-term readouts, particularly the upcoming Phase II data in IR NMIBC where achieving a three-month complete response rate of at least 70% could substantially reduce development risk and serve as an important stock catalyst, reinforcing his constructive stance on the shares.

According to TipRanks, Corwin is a 5-star analyst with an average return of 13.4% and a 52.65% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Solid Biosciences, and Cabaletta Bio.

In another report released on February 13, Barclays also maintained a Buy rating on the stock with a $59.00 price target.